
Via Massarenti 9, Bologna 40138
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents
Giovanni Marconi, Elisabetta Petracci, Giuseppe Lanzarone, Calogero Vetro, Maria Paola Martelli, Cristina Papayannidis, Ernesta Audisio, Paola Minetto, Carola Riva, Fabio Guolo … See all authors
First published: 20 January 2025 https://doi.org/10.1002/ajh.27591
...We than focused on the impact of any pre-treatment comorbidity on overall survival (OS), as reported in Supporting Information S6; cardiovascular disease (HR [95% CI], 1.82 [1.09–3.04], p = 0.022), moderate or severe hepatic dysfunction (5.17 [1.24–21.57], p = 0.024), hypoalbuminemia (2.08 [1.07–4.03] p = 0.031), and thrombocytopenia (2.11 [1.42–3.14], p < 0.001) resulted associated with OS in univariate analysis......
09/03/2025